Abstract
Epidemiological research aims to provide information on the development, prevalence and progression of diseases, and their associated risk factors. Epidemiological research is thus the basis of increasing our understanding on the aetiology of diseases and as a consequence the starting point for identifying at risk groups in the population, development for novel prevention and treatment strategies, and health care planning. This review provides an overview of the epidemiology of Parkinson’s disease, the second most common neurodegenerative disorder, with special emphasis on population-based data on the clinical progression of motor and non-motor features of the disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
(1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N Engl J Med 328:176–183
Adler CH, Thorpy MJ (2005) Sleep issues in Parkinson’s disease. Neurology 64:S12–S20
Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448–458
Allam MF, Del Castillo AS, Navajas RF (2005) Parkinson’s disease risk factors: genetic, environmental, or both? Neurol Res 27:206–208
Allcock LM, Ullyart K, Kenny RA, Burn DJ (2004) Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:1470–1471
Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, Ferini-Strambi L (2005) Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165:1286–1292
Alves G, Kurz M, Lie SA, Larsen JP (2004) Cigarette smoking in Parkinson’s disease: influence on disease progression. Mov Disord 19:1087–1092
Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D (2006) Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 21:1123–1130
Alves G, Wentzel-Larsen T, Larsen JP (2004) Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 63:1908–1911
Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2005) Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 65:1436–1441
Autere JM, Moilanen JS, Myllyla VV, Majamaa K (2000) Familial aggregation of Parkinson’s disease in a Finnish population. J Neurol Neurosurg Psychiatry 69:107–109
Beyer MK, Herlofson K, Arsland D, Larsen JP (2001) Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 103:7–11
Bhidayasiri R, Truong DD (2008) Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 266:204–215
Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE (2001) Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16:622–630
Boeve BF, Silber MH, Parisi JE, Dickson DW, Ferman TJ, Benarroch EE, Schmeichel AM, Smith GE, Petersen RC, Ahlskog JE, Matsumoto JY, Knopman DS, Schenck CH, Mahowald MW (2003) Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 61:40–45
Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini S, Rossi G, Piaggesi A (2003) Orthostatic hypotension in de novo Parkinson disease. Arch Neurol 60:1400–1404
Braga-Neto P, da Silva-Junior FP, Sueli Monte F, de Bruin PF, de Bruin VM (2004) Snoring and excessive daytime sleepiness in Parkinson’s disease. J Neurol Sci 217:41–45
Bronnick K, Emre M, Lane R, Tekin S, Aarsland D (2007) Profile of cognitive impairment in dementia associated with Parkinson’s disease compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 78:1064–1068
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410
Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG (2006) Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77:585–589
Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70:1017–1022
Cairns V, Godwin J (2005) Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 34:1340–1345
Chaudhuri A, Behan PO (2004) Fatigue in neurological disorders. Lancet 363:978–988
Coleman RM, Pollak CP, Weitzman ED (1980) Periodic movements in sleep (nocturnal myoclonus): relation to sleep disorders. Ann Neurol 8:416–421
Comella CL, Nardine TM, Diederich NJ, Stebbins GT (1998) Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology 51:526–529
de Maindreville AD, Fenelon G, Mahieux F (2005) Hallucinations in Parkinson’s disease: a follow-up study. Mov Disord 20:212–217
Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI (1992) Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:138–142
Dubois B, Pillon B (1997) Cognitive deficits in Parkinson’s disease. J Neurol 244:2–8
Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, Schaid DJ, Rocca WA (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60:91–96
Elbaz A, Tranchant C (2007) Epidemiologic studies of environmental exposures in Parkinson’s disease. J Neurol Sci 262:37–44
Eriksen JL, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62:353–357
Fahn S (2003) Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14
Fahn S, Elton RL (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DM, Lieberman A (eds) Recent development in Parkinson’s disease. MacMillan Health Care Information, Florham Park, NJ, pp 153–163
Fenelon G (2008) Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13:18–25
Fenelon G, Goetz CG, Karenberg A (2006) Hallucinations in Parkinson disease in the prelevodopa era. Neurology 66:93–98
Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733–745
Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, Holmes J, Kingdom WK, MacMahon DG, Peto V, Playfer JR (2003) Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord 18:1139–1145
Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 127:550–560
Gagnon JF, Bedard MA, Fantini ML, Petit D, Panisset M, Rompre S, Carrier J, Montplaisir J (2002) REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology 59:585–589
Gandhi S, Wood NW (2005) Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet 14:2749–2755
Garber CE, Friedman JH (2003) Effects of fatigue on physical activity and function in patients with Parkinson’s disease. Neurology 60:1119–1124
Garcia-Borreguero D, Larrosa O, Bravo M (2003) Parkinson’s disease and sleep. Sleep Med Rev 7:115–129
Vazquez A, Sanchez Bernardos V, Vazquez A (2004) Motor complications in Parkinson disease: a prospective follow-up study. Clin Neuropharmacol 27:49–52
Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznai B, Fabrizio E, Vieregge P, Horstmann RD (1998) A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nat Genet 18:262–265
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39
Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, Tanner C (2001) Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56:1712–1721
Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2006) Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 67:853–858
Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP (2008) Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson’s disease over time. J Neurol Neurosurg Psychiatry 79:387–391
Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP (2007) Insomnia in Parkinson’s disease: frequency and progression over time. J Neurol Neurosurg Psychiatry 78:476–479
Gjerstad MD, Aarsland D, Larsen JP (2002) Development of daytime somnolence over time in Parkinson’s disease. Neurology 58:1544–1546
Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB (2001) Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 57:2078–2082
Goetz CG, Tanner CM, Stebbins GT, Buchman AS (1988) Risk factors for progression in Parkinson’s disease. Neurology 38:1841–1844
Grimbergen YA, Munneke M, Bloem BR (2004) Falls in Parkinson’s disease. Curr Opin Neurol 17:405–415
Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22:839–842
Hagell P, Nordling S, Reimer J, Grabowski M, Persson U (2002) Resource use and costs in a Swedish cohort of patients with Parkinson’s disease. Mov Disord 17:1213–1220
Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK (2008) Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70:1456–1460
Hauser RA, McDermott MP, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63:1756–1760
Hely MA, Morris JG, Reid WG, O’Sullivan DJ, Williamson PM, Broe GA, Adena MA (1995) Age at onset: the major determinant of outcome in Parkinson’s disease. Acta Neurol Scand 92:455–463
Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20:190–199
Herlofson K, Larsen JP (2003) The influence of fatigue on health-related quality of life in patients with Parkinson’s disease. Acta Neurol Scand 107:1–6
Herlofson K, Lie SA, Arsland D, Larsen JP (2004) Mortality and Parkinson disease: A community based study. Neurology 62:937–942
Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, Rudolf J, Herholz K, Heiss WD (2005) Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 62:378–382
Hoehn M, Yahr M (1967) Parkinsonism: Onset, progression, and mortality. Neurology 17:427–442
Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression and mortality. Neurology 17:427–442
Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70:734–738
Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: A clinicopathologic study. Neurology 42:1142–1146
Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–870
Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 50:140–148
Hughes AJ, Daniel SE, Lees AJ (1993) The clinical features of Parkinson’s disease in 100 histologically proven cases. Adv Neurol 60:595–599
Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 57:1497–1499
Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 54:1596–1602
Hui JS, Murdock GA, Chung JS, Lew MF (2005) Behavioral changes as side effects of medication treatment for Parkinson’s disease. Adv Neurol 96:114–129
Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I (2002) Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov Disord 17:366–371
Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, et al. (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40:1529–1534
Janvin C, Aarsland D, Larsen JP, Hugdahl K (2003) Neuropsychological profile of patients with Parkinson’s disease without dementia. Dement Geriatr Cogn Disord 15:126–131
Kandinov B, Giladi N, Korczyn AD (2007) The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson’s disease. Parkinsonism Relat Disord 13:243–245
Karlsen KH, Larsen JP, Tandberg E, Maeland JG (1999) Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66:431–435
Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ (2004) Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:1749–1752
Keranen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, Kola H, Ylikoski A, Satomaa O, Kovanen J, Taimela E, Haapaniemi H, Turunen H, Takala A (2003) Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 9:163–168
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605–608
Koller WC, Hutton JT, Tolosa E, Capilldeo R (1999) Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 53:1012–1019
Korchounov A, Kessler KR, Yakhno NN, Damulin IV, Schipper HI (2005) Determinants of autonomic dysfunction in idiopathic Parkinson’s disease. J Neurol 252:1530–1536
Krishnan PR, Bhatia M, Behari M (2003) Restless legs syndrome in Parkinson’s disease: a case-controlled study. Mov Disord 18:181–185
Kurz M, Alves G, Aarsland D, Larsen JP (2003) Familial Parkinson’s disease: a community-based study. Eur J Neurol 10:159–163
Lai BC, Marion SA, Teschke K, Tsui JK (2002) Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat Disord 8:297–309
Larsen JP, Karlsen K, Tandberg E (2000) Clinical problems in non-fluctuating patients with Parkinson’s disease: a community-based study. Mov Disord 15:826–829
Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18:414–418
Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH (1998) Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson’s disease. Hum Genet 103:424–427
Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, Stern Y, Marder K (2002) Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 51:722–729
Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K (2000) Motor impairment in PD: relationship to incident dementia and age. Neurology 55:539–544
Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, Stern Y, Marder K (2002) The association of incident dementia with mortality in PD. Neurology 59:1708–1713
Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I (1998) Apathy is not depression. J Neuropsychiatry Clin Neurosci 10:314–319
Litvan I (1998) Parkinsonian features: when are they Parkinson disease? Jama 280:1654–1655
Loo HV, Tan EK (2008) Case-control study of restless legs syndrome and quality of sleep in Parkinson’s disease. J Neurol Sci 266:145–149
Lou JS, Kearns G, Oken B, Sexton G, Nutt J (2001) Exacerbated physical fatigue and mental fatigue in Parkinson’s disease. Mov Disord 16:190–196
Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K (1999) Progression of parkinsonian signs in Parkinson disease. Arch Neurol 56:334–337
Lu J, Jhou TC, Saper CB (2006) Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 26:193–202
Marder K, Tang MX, Cote L, Stern Y, Mayeux R (1995) The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 52:695–701
Marin RS (1991) Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 3:243–254
Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE (2005) Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 64:87–93
Marras C, Rochon P, Lang AE (2002) Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 59:1724–1728
McKeith IG (2006) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 9:417–423
Meara J, Bhowmick BK, Hobson P (1999) Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing 28:99–102
Mesholam RI, Moberg PJ, Mahr RN, Doty RL (1998) Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Arch Neurol 55:84–90
Mizuno S, Miyaoka T, Inagaki T, Horiguchi J (2005) Prevalence of restless legs syndrome in non-institutionalized Japanese elderly. Psychiatry Clin Neurosci 59:461–465
Mjones H (1949) Paralysis agitans: a clinical and genetic study. Acta Psychiatr Neurol Scand 54(Suppl):1–195
Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P (1997) Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 12:61–65
Morrish PK (2003) How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson’s disease? Mov Disord 18(Suppl 7):S63–S70
Morrish PK, Sawle GV, Brooks DJ (1996) An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain 119(Pt 2):585–591
Muller A, Reichmann H, Livermore A, Hummel T (2002) Olfactory function in idiopathic Parkinson’s disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 109:805–811
Muller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I (2000) Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 55:888–891
Myslobodsky M, Lalonde FM, Hicks L (2001) Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatry Neurol 14:120–124
Nilsson FM, Kessing LV, Bolwig TG (2001) Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 104:380–386
Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG (2002) Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 106:202–211
Nomura T, Inoue Y, Miyake M, Yasui K, Nakashima K (2006) Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson’s disease. Mov Disord 21:380–384
Oka H, Mochio S, Onouchi K, Morita M, Yoshioka M, Inoue K (2006) Cardiovascular dysautonomia in de novo Parkinson’s disease. J Neurol Sci 241:59–65
Olanow CW (2007) The pathogenesis of cell death in Parkinson’s disease – 2007. Mov Disord 22(Suppl 17):S335–S342
Olanow CW, Schapira AH, Roth T (2000) Waking up to sleep episodes in Parkinson’s disease. Mov Disord 15:212–215
Ondo WG, Vuong KD, Jankovic J (2002) Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59:421–424
Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44:595–600
Patel V, Kirkwood BR, Weiss H, Pednekar S, Fernandes J, Pereira B, Upadhye M, Mabey D (2005) Chronic fatigue in developing countries: population based survey of women in India. BMJ 330:1190
Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, Edwardson JA, Ince P, Blessed G, Irving D, et al. (1991) Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease. Ann N Y Acad Sci 640:197–202
Pickering RM, Grimbergen YA, Rigney U, Ashburn A, Mazibrada G, Wood B, Gray P, Kerr G, Bloem BR (2007) A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov Disord 22:1892–1900
Pluck GC, Brown RG (2002) Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 73:636–642
Poewe WH, Wenning GK (1998) The natural history of Parkinson’s disease. Ann Neurol 44:S1–S9
Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173–181
Post B, Merkus MP, de Haan RJ, Speelman JD (2007) Prognostic factors for the progression of Parkinson’s disease: a systematic review. Mov Disord 22:1839–1851; quiz 1988
Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ (2002) Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 17:867–876
Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061–1068
Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189; quiz 313
Rippon GA, Marder KS (2005) Dementia in Parkinson’s disease. Adv Neurol 96:95–113
Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63:167–173
Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K (2000) Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology 54:1064–1068
Rye DB, Bliwise DL, Dihenia B, Gurecki P (2000) FAST TRACK: daytime sleepiness in Parkinson’s disease. J Sleep Res 9:63–69
Saper CB, Scammell TE, Lu J (2005) Hypothalamic regulation of sleep and circadian rhythms. Nature 437:1257–1263
Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W (2007) Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 22:1229–1238
Schrag A, Ben-Shlomo Y, Quinn N (2002) How common are complications of Parkinson’s disease? J Neurol 249:419–423
Schrag A, Ben-Shlomo Y, Quinn N (2002) How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Psychiatry 73:529–534
Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP (2007) Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 22:938–945
Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69:308–312
Seppi K, Schocke MF (2005) An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol 18:370–375
Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2000) Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 15:669–677
Shulman LM (2007) Gender differences in Parkinson’s disease. Gend Med 4:8–18
Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 16:507–510
Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H (2004) Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19:1196–1202
Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R (2005) Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics 23:817–836
Stenager EN, Wermuth L, Stenager E, Boldsen J (1994) Suicide in patients with Parkinson’s disease. An epidemiological study. Acta Psychiatr Scand 90:70–72
Stolze H, Klebe S, Zechlin C, Baecker C, Friege L, Deuschl G (2004) Falls in frequent neurological diseases – prevalence, risk factors and aetiology. J Neurol 251:79–84
Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ (2006) Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:968–975
Tan EK (2006) Restless legs syndrome and Parkinson’s disease: is there an etiologic link? J Neurol 253(Suppl 7):VII33–VII37
Tan EK, Seah A, See SJ, Lim E, Wong MC, Koh KK (2001) Restless legs syndrome in an Asian population: A study in Singapore. Mov Disord 16:577–579
Tandberg E, Larsen JP, Karlsen K (1998) A community-based study of sleep disorders in patients with Parkinson’s disease. Mov Disord 13:895–899
Tandberg E, Larsen JP, Aarsland D, Cummings JL (1996) The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol 53:175–179
Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL (1997) Risk factors for depression in Parkinson disease. Arch Neurol 54:625–630
Tanner CM, Aston DA (2000) Epidemiology of Parkinson’s disease and akinetic syndromes. Curr Opin Neurol 13:427–430
Taylor KS, Cook JA, Counsell CE (2007) Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry 78:905–906
Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245:519–522
Tison F, Crochard A, Leger D, Bouee S, Lainey E, El Hasnaoui A (2005) Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 65:239–246
Tolosa E, Compta Y, Gaig C (2007) The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord 13(Suppl):S2–S7
Twelves D, Perkins KS, Counsell C (2003) Systematic review of incidence studies of Parkinson’s disease. Mov Disord 18:19–31
Uitti RJ, Baba Y, Wszolek ZK, Putzke DJ (2005) Defining the Parkinson’s disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. Parkinsonism Relat Disord 11:139–145
Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35–p36. Am J Hum Genet 68:895–900
Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022
van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, Testers L, Breedveld GJ, Horstink M, Sandkuijl LA, van Swieten JC, Oostra BA, Heutink P (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69:629–634
Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ (2007) Patient-reported autonomic symptoms in Parkinson disease. Neurology 69:333–341
Verhagen L (2006) Depression in Parkinson’s disease: epidemiology and clinical features. In: Woltes EC, Berendse HW, Stam CJ (eds) Mental dysfunction in Parkinson’s disease III. VU University Press, Amsterdam, pp 176–188
von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 15:473–490
White L, Petrovitch H, Ross GW, Masaki KH, Abbott RD, Teng EL, Rodriguez BL, Blanchette PL, Havlik RJ, Wergowske G, Chiu D, Foley DJ, Murdaugh C, Curb JD (1996) Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. Jama 276:955–960
Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787–1798
Williams DR, Watt HC, Lees AJ (2006) Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 77:468–473
Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA (2002) Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 59:408–413
Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607
Aarsland D, Alves G, Larsen JP (2005) Disorders of motivation, sexual conduct, and sleep in Parkinson’s disease. Adv Neurol 96:56–64
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392
Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56:730–736
Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, Kragh-Sorensen P (2004) The rate of cognitive decline in Parkinson disease. Arch Neurol 61:1906–1911
Aarsland D, Kvaloy JT, Andersen K, Larsen JP, Tang MX, Lolk A, Kragh-Sorensen P, Marder K (2007) The effect of age of onset of PD on risk of dementia. J Neurol 254:38–45
Aarsland D, Larsen JP, Cummins JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56:595–601
Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL (1999) Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:492–496
Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 48:938–942
Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M (2005) Clinical features of LRRK2-associated Parkinson’s disease in central Norway. Ann Neurol 57:762–765
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alves, G., Forsaa, E.B., Pedersen, K.F. et al. Epidemiology of Parkinson’s disease. J Neurol 255 (Suppl 5), 18–32 (2008). https://doi.org/10.1007/s00415-008-5004-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-008-5004-3